Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Consensus PT from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $32.50.

GLUE has been the topic of several research reports. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. boosted their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Finally, Wells Fargo & Company dropped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $18.81 on Friday. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -12.71 and a beta of 1.62. Monte Rosa Therapeutics has a fifty-two week low of $3.90 and a fifty-two week high of $25.77. The firm has a fifty day moving average price of $17.88 and a two-hundred day moving average price of $17.93.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. As a group, sell-side analysts expect that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

Insider Transactions at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer owned 613,471 shares in the company, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the transaction, the insider owned 22,693 shares in the company, valued at approximately $410,743.30. The trade was a 52.58% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,150 shares of company stock worth $668,694. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC bought a new stake in Monte Rosa Therapeutics in the fourth quarter valued at about $30,000. Nisa Investment Advisors LLC increased its stake in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after acquiring an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the period. Seven Fleet Capital Management LP bought a new stake in Monte Rosa Therapeutics in the fourth quarter valued at about $63,000. Finally, Russell Investments Group Ltd. bought a new stake in Monte Rosa Therapeutics in the third quarter valued at about $32,000. Institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.